What is the recommended treatment for essential tremors?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Essential Tremor

Propranolol (80-240 mg/day) or primidone should be initiated as first-line treatment for essential tremor when symptoms interfere with function or quality of life, with both medications effective in up to 70% of patients. 1

First-Line Pharmacological Treatment

The American Academy of Neurology establishes propranolol and primidone as the two evidence-based first-line options for essential tremor 1. These medications have been used for over 40 years with demonstrated efficacy 1.

Key treatment principles:

  • Only initiate medication when tremor interferes with function or quality of life 1
  • Both propranolol and primidone reduce tremor severity by approximately 50% in responsive patients 2, 3
  • If one agent fails, the other should be tried before moving to second-line options 1
  • The two medications can be combined if monotherapy provides inadequate control 2

Propranolol Dosing and Mechanism

  • Dosage range: 80-240 mg/day 1
  • Works by blocking peripheral effects of adrenaline and modulating noradrenergic GABA outflow centrally 4
  • Decreases corticospinal excitability and increases short afferent inhibition 4

Primidone Considerations

  • Has intrinsic anti-tremor properties independent of its phenobarbital metabolite 1
  • Clinical benefits may not appear for 2-3 months, requiring an adequate trial period 1
  • Modulates GABA-A and GABA-B intracortical circuits and blocks voltage-gated sodium channels 4
  • Better baseline cerebellar function (measured by eyeblink classical conditioning) predicts better response 4

Important Contraindications and Precautions

Beta-blockers like propranolol must be avoided in patients with: 1, 5

  • Chronic obstructive pulmonary disease or asthma
  • Bradycardia or heart block
  • Congestive heart failure

Common adverse effects of beta-blockers include: 1

  • Fatigue and depression
  • Dizziness and hypotension
  • Exercise intolerance and sleep disorders
  • Cold extremities and bronchospasm

Primidone-specific concerns: 1

  • Behavioral disturbances, irritability, and sleep disturbances at higher doses
  • Teratogenic risks (neural tube defects) - counsel women of childbearing age

Clinical pearl: For patients with both essential tremor and hypertension, propranolol provides dual therapeutic benefits 1, 5

Second-Line Pharmacological Options

If first-line agents fail or are contraindicated, consider: 1, 2

  • Carbamazepine - generally less effective than first-line therapies
  • Gabapentin - limited evidence for moderate efficacy
  • Topiramate - may provide benefit in selected cases 6
  • Benzodiazepines (clonazepam) - can be helpful, particularly for stress-induced tremor 2

Alternative Beta-Blockers

If propranolol causes adverse effects, other beta-blockers may be tried, though they are generally less effective: 1, 2

  • Nadolol: 40-320 mg daily
  • Metoprolol: 25-100 mg extended release daily or twice daily
  • Atenolol: limited evidence for moderate effect
  • Timolol: 20-30 mg/day

Surgical Interventions for Medication-Refractory Tremor

Surgical therapies should be considered when medications fail due to lack of efficacy at maximum doses, dose-limiting side effects, or medical contraindications. 1

Treatment Algorithm for Surgical Candidates

For unilateral tremor or patients with medical comorbidities:

  • Magnetic resonance-guided focused ultrasound (MRgFUS) thalamotomy is preferred 1
  • Shows sustained tremor improvement of 56% at 4 years 1
  • Lowest complication rate: 4.4% compared to radiofrequency thalamotomy (11.8%) and DBS (21.1%) 1, 5
  • Early adverse effects include gait disturbance (36%) and paresthesias (38%), decreasing to 9% and 14% by 1 year 1
  • Serious adverse events are rare (1.6%) 1

MRgFUS contraindications: 1, 5

  • Cannot undergo MRI
  • Skull density ratio <0.40
  • Bilateral treatment needed
  • Previous contralateral thalamotomy

For bilateral tremor or MRgFUS contraindications:

  • Deep brain stimulation (DBS) of the ventral intermediate nucleus (VIM) of the thalamus 1, 6
  • Provides adjustable, reversible tremor control that can be optimized over time 1
  • Approximately 90% tremor control rate 2
  • Preferred for younger patients as it offers long-term adjustability 1

Radiofrequency thalamotomy:

  • Available but carries higher complication risks than MRgFUS 1
  • Reserved for cases where DBS and MRgFUS are not feasible 1

Common Pitfalls to Avoid

  • Do not prescribe beta-blockers without screening for contraindications - particularly important in elderly patients with cardiac or pulmonary comorbidities 7, 1
  • Do not abandon primidone prematurely - allow 2-3 months for clinical benefit to manifest 1
  • Do not use aspirin or other inadequate treatments - propranolol and primidone are the only evidence-based first-line options 1
  • Do not delay surgical referral in severely disabled patients - surgical options provide superior tremor control (approximately 90%) compared to medications (approximately 50%) 2, 3
  • Regular assessment of tremor severity and medication side effects is essential - dose adjustments may be needed based on clinical response and tolerability 1

References

Guideline

Medications for Tremor Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of essential tremor: current status.

Postgraduate medical journal, 2020

Guideline

Differentiating Essential Tremor from Intentional Tremor

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Managing Essential Tremor.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2020

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.